Faeth Therapeutics, Inc. Stock Split Ratio
Faeth Therapeutics, Inc. (FTH) had Stock Split Ratio of 5.00% as of 2025-06-16, per its 10-Q filed 2026-05-15.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-05-15
- 2025-06-16: Stockholders' Equity Note, Stock Split, Conversion Ratio 5.00%.
- 2021-01-29: Stockholders' Equity Note, Stock Split, Conversion Ratio 2.08%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2025-06-16 | 5.00% 10-Q · filed 2026-05-15 |
| 2021-01-29 | 2.08% 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |